Orchard Therapeutics plc - ADR

0.00 (+0.84%)
Earnings Announcements

Orchard Therapeutics Reports Q3 2022 Financial Results

Published: 11/14/2022 12:46 GMT
Orchard Therapeutics plc - ADR (ORTX) - Orchard Therapeutics Reports Third Quarter 2022 Financial Results and Reviews Recent Business Highlights.
Ended Q3 With $146.6m of Cash and Investments and Runway Now Into Q2 of 2024.
Clinical Type B Meeting With U.S. FDA to Take Place in Early 2023 Prior to Otl-200 Bla Submission.
Qtrly Loss per Share $0.37.
Qtrly Revenue $5.8 Million Versus $1.2 Million.
Q3 Earnings per Share View $-0.24, Revenue View $4.4 Million -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $4.56 Million
Adjusted EPS is expected to be -$0.22

Next Quarter Revenue Guidance is expected to be $5.33 Million
Next Quarter EPS Guidance is expected to be -$0.20

More details on our Analysts Page.